Insulin-like growth factor (IGF) pathway activity has been reported in MET-amplified gastric cancer cells [16, 17] and the pathway has been proposed as a means by which HER2-amplified NCI-N87 circumvent lapatinib inhibition [18]. This evidence concerns the gene ERBB2 and gastric cancer.